Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C

World Journal of Gastroenterology

Volumn 16, Issue 35, 2010, Pages 4394-4399

  Ji, Fan Pu ^a   Li, Zheng Xiao ^a   Deng, Hong ^a   Xue, Hong An ^a   Liu, Yuan ^a   Li, Min ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Chronic hepatitis C; Corticosteroid therapy; Interferon ; Interstitial pneumonitis; Management

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CORTICOSTEROID; METHYLPREDNISOLONE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISOLONE; RIBAVIRIN; XIAO CHAI HU TANG;

ANOREXIA; ARTHRALGIA; ARTICLE; CHRONIC HEPATITIS; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; COUGHING; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; DYSPNEA; FATALITY; FATIGUE; FEVER; HEPATITIS C; HUMAN; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; LUNG COMPLICATION; LUNG LAVAGE; LUNG TOXICITY; MYALGIA;

EID: 77957596635     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i35.4394     Document Type: Article

References (33)

1. Kamisako T, Adachi Y, Chihara J, Yamamoto T. Interstitial pneumonitis and interferon-alfa. BMJ 1993; 306: 896
2. Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994; 105: 939-941
3. Moriya K, Yasuda K, Koike K, Ichinose Y, Yotsuyanagi H, Kurokawa K, Iino S. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J Gastro-enterol 1994; 29: 514-517
4. Hizawa N, Kojima J, Kojima T, Sukoh N, Yamaguchi E, Kawakami Y, Matsushima T. A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after alpha-interferon administration. Intern Med 1994; 33: 337-341
5. Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, Ito S, Kuriyama M, Nakai T, Kitagawa M. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 1996; 9: 2691-2696
6. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291
7. Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am J Med Sci 2001; 322: 233-235
8. Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, Brown RS Jr. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002; 97: 2432-2440
9. Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK Jr. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest 2003; 124: 406-410
10. Midturi J, Sierra-Hoffman M, Hurley D, Winn R, Beissner R, Carpenter J. Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature. Clin Infect Dis 2004; 39: 1724-1729
11. Fuhrmann V, Kramer L, Bauer E, Laferl H, Tucek G, Dekan G, Schenk P. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection. Dig Dis Sci 2004; 49: 1966-1970
12. Renou C, Germain S, Harafa A, Martin S, Larroque O, Muller P, Bertrand JJ, Halfon P. Interstitial pneumonia recurrence during chronic hepatitis C treatment. Am J Gastroenterol 2005; 100: 1625-1626
13. Hillier AE, Mand J, Raza A, Markov M, Nadir A. Consensus interferon induced interstitial pneumonitis in a patient with HCV. Am J Gastroenterol 2006; 101: 200-202
14. Chen YC, Lu SN, Lin MC. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Chang Gung Med J 2007; 30: 92-97
15. Carrillo-Esper R, González-Avila D, Uribe-Ríos M, Méndez-Sánchez N. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report. Ann Hepatol 2008; 7: 87-90
16. Ji FP, Li ZX, Deng H, Xue HA, Liu Y, Li M. [Clinical features of interstitial pneumonitis due to interferon alpha therapy for chronic hepatitis C] Nanfang Yike Daxue Xuebao 2009; 29: 667-670
17. Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci 2010; 55: 579-585
18. Alazemi S, Campos MA. Interferon-induced sarcoidosis. Int J Clin Pract 2006; 60: 201-211
19. Monsuez JJ, Carcelain G, Charniot JC, Barrière J, Duclos-Vallée JC, Parent F, Autran B. T cells subtypes in a patient with interferon-alpha induced sarcoidosis. Am J Med Sci 2009; 337: 60-62
20. Arora A, Vargas L, Kuzniar TJ. Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C. J Hosp Med 2009; 4: E45-E46
21. Bini EJ, Weinshel EH. Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C. Mayo Clin Proc 1999; 74: 367-370
22. Solsky J, Liu J, Peng M, Schaerer M, Tietz A. Rate of interstitial pneumonitis among hepatitis virus C-infected patients treated with pegylated interferon. J Hepatol 2009; 50 Suppl 1: S238
23. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112: 1017-1021
24. Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol 1998; 25: 3-8
25. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672
26. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32: 647-653
27. Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004; 25: 25-35
28. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315
29. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259
30. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968
31. Sharma S, Maycher B. Is HRCT the best way to diagnose idiopathic interstitial fibrosis? Curr Opin Pulm Med 2006; 12: 323-330
32. Magy N, Cribier B, Schmitt C, Ellero B, Jaeck D, Boudjema K, Wolf P, Labouret N, Doffoel M, Kirn A, Stoll-Keller F. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999; 21: 253-261
33. Henry SD, Metselaar HJ, Van Dijck J, Tilanus HW, Van Der Laan LJ. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci 2007; 1110: 439-447